Literature DB >> 9407564

Response of premature infants with severe respiratory failure to inhaled nitric oxide. Preemie NO Collaborative Group.

K P Van Meurs1, W D Rhine, J M Asselin, D J Durand.   

Abstract

Elevated pulmonary vascular resistance is seen in premature infants with severe respiratory distress syndrome (RDS). Inhaled nitric oxide (NO) has been shown to decrease pulmonary vascular resistance and to improve oxygenation in some patients with respiratory failure. The purpose of this study was to determine whether premature infants with severe RDS would respond to inhaled NO with an improvement in oxygenation. Eleven premature infants (mean gestational age 29.8 weeks) with severe respiratory failure caused by RDS were treated with NO in four concentrations [1, 5, 10, 20 parts per million (ppm) NO] and with placebo (0 ppm NO). Arterial blood gas measurements were drawn immediately before and at the end of each of the 15-minute treatments and were used to determine the arterial/alveolar oxygen ratio (PaO2/PAO2). Ten of the 11 infants had a greater than 25% increase in PaO2/PAO2. Five of the 11 had a greater than 50% increase in PaO2/PAO2. Despite normal cranial ultrasound imaging prior to NO, 3 infants had intracranial hemorrhage (ICH) noted on their first ultrasound scan after this brief period of NO treatment, and 4 additional infants developed ICH later during their hospitalization. No infant had significant elevations of methemoglobin concentrations after the total 60-minute exposure to NO. NO may be an effective method of improving oxygenation in infants with severe RDS. The disturbing incidence of ICH in this small group of infants needs to be carefully evaluated before considering routine use or NO for preterm infants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407564     DOI: 10.1002/(sici)1099-0496(199711)24:5<319::aid-ppul3>3.0.co;2-d

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  12 in total

Review 1.  Response to inhaled nitric oxide in premature and term neonates.

Authors:  T Hoehn; M F Krause
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 3.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 4.  Is nitric oxide effective in preterm infants?

Authors:  Nimish Subhedar; Chris Dewhurst
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09       Impact factor: 5.747

5.  Safety and efficacy of nitric oxide in chronic lung disease.

Authors:  P L Clark; I I Ekekezie; H A Kaftan; C A Castor; W E Truog
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-01       Impact factor: 5.747

Review 6.  Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant.

Authors:  Gregory M Sokol; Girija G Konduri; Krisa P Van Meurs
Journal:  Semin Perinatol       Date:  2016-10       Impact factor: 3.300

Review 7.  CO and NO pulmonary diffusing capacity during pregnancy: Safety and diagnostic potential.

Authors:  Gerald S Zavorsky; Arlin B Blood; Gordon G Power; Lawrence D Longo; Raul Artal; Emanuel J Vlastos
Journal:  Respir Physiol Neurobiol       Date:  2010-02-10       Impact factor: 1.931

8.  A comparison of indices of respiratory failure in ventilated preterm infants.

Authors:  N V Subhedar; A T Tan; E M Sweeney; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

Review 9.  Inhaled nitric oxide and neuroprotection in preterm infants.

Authors:  Jeremy D Marks; Michael D Schreiber
Journal:  Clin Perinatol       Date:  2008-12       Impact factor: 3.430

Review 10.  Inhaled nitric oxide for respiratory failure in preterm infants.

Authors:  Keith J Barrington; Neil Finer; Thomas Pennaforte
Journal:  Cochrane Database Syst Rev       Date:  2017-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.